Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension

K Morrisroe; W Stevens; M Huq; D Prior; J Sahhar; GS Ngian; D Celermajer; J Zochling; S Proudman; M Nikpour; C Hill; S Lester; P Nash; G Ngian; M Rischmueller; J Roddy; G Strickland; V Thakkar; J Walker

Journal article

Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension

K Morrisroe, W Stevens, M Huq, D Prior, J Sahhar, GS Ngian, D Celermajer, J Zochling, S Proudman, M Nikpour, C Hill, S Lester, P Nash, G Ngian, M Rischmueller, J Roddy, G Strickland, V Thakkar, J Walker

Arthritis Research and Therapy | BMC | Published : 2017

DOI: 10.1186/s13075-017-1341-x

Download PDF

Abstract

Background: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). We sought to determine survival, predictors of mortality, and health-related quality of life (HRQoL) related to PAH in a large SSc cohort with PAH. Methods: We studied consecutive SSc patients with newly diagnosed (incident) World Health Organization (WHO) Group 1 PAH enrolled in a prospective cohort between 2009 and 2015. Survival methods were used to determine age and sex-adjusted standardised mortality ratio (SMR) and years of life lost (YLL), and to identify predictors of mortality. HRQoL was measured using the Short form 36 (SF-36) instrument. Results: Among 132 SSc-PAH patient..

View full abstract

University of Melbourne Researchers

Wendy Stevens Author

David Prior Author

Mandana Nikpour Author

Katie Morrisroe Author

Related Projects (2)

IMPROVING OUTCOMES IN SYSTEMIC AUTOIMMUNE DISEASE: A COLLABORATIVE AND INTERDISCIPLINARY PROGRAM OF RESEARCH

The multi-organ autoimmune diseases ‘scleroderma’ and ‘lupus’ have a profound negative impact on quality of life and life expectancy. The ov..

QUANTIFYING THE BURDEN OF SYSTEMIC SCLEROSIS IN AUSTRALIA: FROM DATA LINKAGE TO PATIENT REPORTED OUTCOMES

Systemic sclerosis (SSc) is a rare autoimmune disease with the potential to cause significant physical, financial and psychosocial burden on..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This work was supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. Dr Morrisroe holds an NHMRC Scholarship (APP1113954). Dr Nikpour holds an NHMRC Fellowship (APP1071735).